Solid Biosciences (SLDB) Net Cash Flow Growth (3y) (2020 - 2026)
Solid Biosciences (SLDB) Net Cash Flow Growth (3y) (2020 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
NCF Growth (3y) (Qtr) |
| 1 |
Alterity Therapeutics |
814,307.08 Bn |
814,307.05 Bn |
- |
- |
| 2 |
Belite Bio |
55,320.00 Bn |
55,320.00 Bn |
- |
- |
| 3 |
Quantum Biopharma |
17,149.72 Bn |
17,149.72 Bn |
- |
- |
| 4 |
Legend Biotech |
3,590.00 Bn |
3,589.71 Bn |
242.10 Mn |
89.97% |
| 5 |
Akari Therapeutics |
1,650.72 Bn |
1,650.72 Bn |
- |
-13.44% |
| 6 |
Evaxion A |
1,522.09 Bn |
1,522.07 Bn |
- |
- |
| 7 |
Psyence Biomedical |
229.39 Bn |
229.38 Bn |
- |
- |
| 8 |
Vertex Pharmaceuticals |
113.09 Bn |
105.85 Bn |
2.59 Bn |
33.37% |
| 9 |
Abivax |
90.15 Bn |
90.15 Bn |
- |
- |
| 10 |
Solid Biosciences |
789.54 Mn |
408.86 Mn |
- |
194.46% |
| Date | Value |
|---|
| Mar 31, 2026 |
194.46% |
| Dec 31, 2025 |
-26.27% |
| Sep 30, 2025 |
-141.30% |
| Jun 30, 2025 |
1.64% |
| Mar 31, 2025 |
131.04% |
| Dec 31, 2024 |
19.19% |
| Sep 30, 2024 |
29.81% |
| Jun 30, 2024 |
31.06% |
| Mar 31, 2024 |
-27.38% |
| Dec 31, 2023 |
171.58% |
| Sep 30, 2023 |
-39.57% |
| Jun 30, 2023 |
-81.09% |
| Mar 31, 2023 |
33.99% |
| Dec 31, 2022 |
97.42% |
| Sep 30, 2022 |
28.77% |
| Jun 30, 2022 |
-226.92% |
| Mar 31, 2022 |
32.51% |
| Dec 31, 2021 |
30.44% |
| Sep 30, 2021 |
-75.97% |
| Jun 30, 2021 |
-51.45% |
